BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1543357)

  • 1. [Antiemetics and its clinical evaluations].
    Furue H
    Gan To Kagaku Ryoho; 1992 Mar; 19(3):294-301. PubMed ID: 1543357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
    Oo TH; Hesketh PJ
    Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The control of chemotherapy-induced nausea and vomiting].
    Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
    Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment of nausea and vomiting caused by cancer chemotherapy].
    Havsteen H; Kjaer M
    Ugeskr Laeger; 1989 Feb; 151(7):430-4. PubMed ID: 2645736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
    Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
    Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of nausea and vomiting caused by anticancer drugs: state of the art.
    Pisters KM; Kris MG
    Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of antiemetics in cancer chemotherapy].
    Ghosn M; Droz JP
    J Med Liban; 1992; 40(2):106-7. PubMed ID: 1339878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of diazepam on delayed nausea and vomiting caused by anticancer agents].
    Tong FZ; Zhang JQ; Qiao XM; Mao YC; Meng FY; Liu HJ; Hui S; Zhu FX; Shu W; Hong J
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):391-5. PubMed ID: 9492833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.